 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
12 News |  |
- dimethyl fumarate controlled release (FP 187) / Forward Pharma
Enrollment change, Trial withdrawal, Trial primary completion date: Proof-of-concept Study of Forward Pharma (FP)187 in Patients With Mild/Moderate Psoriatic Arthritis (clinicaltrials.gov) - Oct 25, 2016
P2, N=0, Withdrawn, Sponsor: Skåne University Hospital
N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Oct 2016
- dimethyl fumarate controlled release (FP 187) / Forward Pharma
Enrollment change, Trial withdrawal, Head-to-Head: Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Aug 10, 2016
P3, N=0, Withdrawn, Sponsor: Forward-Pharma GmbH
N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Oct 2016 N=500 --> 0 | Not yet recruiting --> Withdrawn
- ||||| dimethyl fumarate controlled release (FP 187) / Forward Pharma
Trial initiation date, Head-to-Head: Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Feb 4, 2016
P3, N=500, Not yet recruiting, Sponsor: Forward-Pharma GmbH
N=500 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Jun 2015 --> Jun 2016
- dimethyl fumarate controlled release (FP 187) / Forward Pharma
New P2 trial: Proof-of-concept Study of Forward Pharma (FP)187 in Patients With Mild/Moderate Psoriatic Arthritis (clinicaltrials.gov) - Jun 18, 2015
P2, N=30, Recruiting, Sponsor: Skåne University Hospital
- ||||| dimethyl fumarate controlled release (FP 187) / Forward Pharma
Trial initiation date, Trial primary completion date, Head-to-Head: Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Mar 7, 2015
P3, N=500, Not yet recruiting, Sponsor: Forward-Pharma GmbH
Initiation date: Jun 2015 --> Jun 2016 Initiation date: Sep 2013 --> Jun 2015 | Trial primary completion date: Aug 2014 --> Jun 2017
- ||||| dimethyl fumarate controlled release (FP 187) / Forward Pharma
Enrollment change, Head-to-Head: Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Aug 1, 2013
P3, N=500, Not yet recruiting, Sponsor: Forward-Pharma GmbH
Initiation date: Sep 2013 --> Jun 2015 | Trial primary completion date: Aug 2014 --> Jun 2017 N=750 --> 500
- |||||||||| dimethyl fumarate controlled release (FP 187) / Forward Pharma
New P3 trial, Head-to-Head: Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Mar 19, 2013
P3, N=500, Not yet recruiting, Sponsor: Forward-Pharma GmbH
- |||| dimethyl fumarate controlled release (FP 187) / Forward Pharma
Trial completion: Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Dec 8, 2012
P2, N=252, Completed, Sponsor: Forward-Pharma GmbH
N=750 --> 500 Active, not recruiting --> Completed
- ||| dimethyl fumarate controlled release (FP 187) / Forward Pharma
Enrollment change: Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Feb 6, 2012
P2, N=252, Completed, Sponsor: Forward-Pharma GmbH
Active, not recruiting --> Completed N=180 --> 252